To expand and promote cancer research in Binzhou, the Center of Cancer Research (CCR) of Binzhou Medical University Hospital was set up in 2014. As the first and most comprehensive cancer research and drug development center, it develops highly clinic-related humanized mouse models, performs high-throughput drug screening to isolate novel cancer specific drug candidates, explores and dissects aberrantly regulated signal pathways and epigenetic modifications in varieties of human malignancy. Our CCR could take full advantage of sufficient clinical resource to build up a strong clinic-oriented cancer research collaboration and development model to guide all our basic biomedical researches destined to our patient services. Currently, the CCR is focusing on investigating the initiation and progression of lung cancers, particularly non small cell lung cancer (NSCLC) to map new potential drug gable cancer targets for translating our bench work findings into updated therapeutic strategies. 

 

So far, we have had nine research members including two senior investigators, five members with PhD degrees and three with Master degrees. Coming from diverse academic backgrounds including clinic medicine, pathology, biochemistry and pharmacology, our group forms a well-cooperated and highly-motivated team.

 

At present, our team is focusing on the followings work:  

1) Establishing Patient-Derived Xenograft(PDX) models and expansion of primary cancer cells. 

2) Exploring molecular mechanism(s) involved in malignant cell transformation and carcinogenesis. 

3) Developing novel cancer therapeutic drugs, including Chinese herbs and new small compounds particularly for sensitizing chemotherapy-resistant lung cancer cells.

 

Specialists 

XI Sichuan

Director of CRC

Professor 

 

Expertise

He is a Senior Scientist of National Cancer Institute (NCI/NIH). Dr. XI Sichuan’s major research focus on the field of lung cancer pathogenic research, particularly the role of chromatin remodeling, post-translational histone modifications,DNA methylation, and non-coding RNA (miRNAs & lncRNAs) change in lung epithelial cells malignant transformation. In-depth study regarding how environmental factors especially the smoking-directed epigenomic variations contribute to lung cancer formation, progression, and transformation. Establishment of all sorts of lung cancer in vitro and in vivo experimental models for the development of more efficient and low toxic lung cancer drugs.  Participation recent years in projects aiming to unveil molecular mechanism of drug resistance during clinical treatment. In charge of four different research projects exploring tumor epigenetics. Participation and completion a joint reward fund (SPORE) and six R01 studies (supported by the national institutes of health research). Now have 65 papers published in the international academic journals. 

 

Thank you for your interest in the Center of Cancer Research. If you are a patient, family member or physician looking for assistance with our clinical services or wishing to schedule an appointment, please contact us for more information:

 

Tel: +86-543-325-8270